Canada Markets closed

BriaCell Therapeutics Corp. (BCT.V)

TSXV - TSXV Delayed Price. Currency in CAD
Add to watchlist
8.80-0.45 (-4.86%)
At close: 3:59PM EDT
Full screen
Previous Close9.25
Open8.61
Bid8.40 x 0
Ask9.15 x 0
Day's Range8.61 - 8.85
52 Week Range0.04 - 27.00
Volume600
Avg. Volume984
Market Cap6.353M
Beta (5Y Monthly)2.21
PE Ratio (TTM)N/A
EPS (TTM)-8.55
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    BriaCell Files Provisional Patent Application for Novel Treatment and Diagnosis of Coronavirus Disease

    BERKELEY, Calif. and VANCOUVER, British Columbia, June 24, 2020 -- BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage.

  • GlobeNewswire

    BriaCell Announces Presentation of Clinical and Scientific Findings at AACR Annual Meeting

    Preliminary safety and efficacy data is being presented today from the clinical trials of Bria-IMT™ alone or in combination with immune checkpoint (PD-1) inhibitors in advanced breast cancer patients. Patients with “moderately” or “well” differentiated tumors showed a higher rate of disease control and clinical benefit than those with “poorly” differentiated tumors. BERKELEY, Calif., and VANCOUVER, British Columbia, June 22, 2020 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (BCT.V) (BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, is announcing the results of clinical studies with its lead product candidate, Bria-IMT™, summarized in a poster session during AACR Annual Meeting 2020, Virtual Meeting II, a virtual event held June 22-24, 2020.

  • GlobeNewswire

    BriaCell CEO to Present at 3rd Annual Next-Gen Immuno-Oncology Congress in June

    BERKELEY, Calif. and VANCOUVER, British Columbia, June 09, 2020 -- BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage.